降糖策略对心脏获益的影响：病理生理学机制。
Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms.
机构信息
LMC Diabetes & Endocrinology, Brampton, Ontario , Canada.
Leadership Sinai Centre for Diabetes, Mount Sinai Hospital , Toronto, Ontario , Canada.
出版信息
Physiology (Bethesda). 2018 May 1;33(3):197-210. doi: 10.1152/physiol.00004.2018.
PMID:29638185
Abstract
Recent trials in Type 2 diabetes (T2D) have shown cardiovascular benefits with specific GLP-1 receptor agonists and SGLT2 inhibitors. We discuss the landscape of outcome trials in T2D from a pathophysiology viewpoint, review current knowledge gaps in underlying mechanisms, propose a caloric fuel routing hypothesis, and highlight areas of future research.
摘要
最近的 2 型糖尿病（T2D）试验表明，特定的 GLP-1 受体激动剂和 SGLT2 抑制剂具有心血管益处。我们从病理生理学的角度讨论了 T2D 的结局试验现状，回顾了潜在机制中的现有知识空白，提出了热量燃料途径假说，并强调了未来研究的领域。
Zotero 插件